...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells.
【24h】

Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells.

机译:通过CD40激活的B细胞从幼稚前体有效生成人同种抗原特异性CD4 +调节性T细胞。

获取原文
获取原文并翻译 | 示例

摘要

CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) play an important role in the induction and maintenance of immune tolerance. Although adoptive transfer of bulk populations of Treg can prevent or treat T cell-mediated inflammatory diseases and transplant allograft rejection in animal models, optimal Treg immunotherapy in humans would ideally use antigen-specific rather than polyclonal Treg for greater specificity of regulation and avoidance of general suppression. However, no robust approaches have been reported for the generation of human antigen-specific Treg at a practical scale for clinical use. Here, we report a simple and cost-effective novel method to rapidly induce and expand large numbers of functional human alloantigen-specific Treg from antigenically naive precursors in vitro using allogeneic nontransformed B cells as stimulators. By this approach naive CD4(+)CD25(-) T cells could be expanded 8-fold into alloantigen-specific Treg after 3 weeks of culture without any exogenous cytokines. The induced alloantigen-specific Treg were CD45RO(+)CCR7(-) memory cells, and had a CD4(high), CD25(+), Foxp3(+), and CD62L (L-selectin)(+) phenotype. Although these CD4(high)CD25(+)Foxp3(+) alloantigen-specific Treg had no cytotoxic capacity, their suppressive function was cell-cell contact dependent and partially relied on cytotoxic T lymphocyte antigen-4 expression. This approach may accelerate the clinical application of Treg-based immunotherapy in transplantation and autoimmune diseases.
机译:CD4(+)CD25(+)Foxp3(+)调节性T细胞(Treg)在诱导和维持免疫耐受中起重要作用。尽管在动物模型中大量Treg的过继转移可以预防或治疗T细胞介导的炎性疾病和移植同种异体移植排斥反应,但理想的人类Treg免疫疗法理想地使用抗原特异性而不是多克隆Treg来提高调节的特异性和避免一般性抑制。但是,尚未报道用于临床规模实用规模的人抗原特异性Treg产生的可靠方法。在这里,我们报告了一种简单且具有成本效益的新颖方法,可以使用同种异体非转化B细胞作为刺激物,从体外的抗原性前体中快速诱导和扩增大量功能性人类同种抗原特异性Treg。通过这种方法,在没有任何外源细胞因子的情况下培养3周后,幼稚的CD4(+)CD25(-)T细胞可以扩增8倍,成为同种抗原特异性Treg。诱导的同种异体抗原特异性Treg是CD45RO(+)CCR7(-)记忆细胞,并具有CD4(高),CD25(+),Foxp3(+)和CD62L(L-选择素)(+)表型。尽管这些CD4(高)CD25(+)Foxp3(+)同种异体抗原特异性Treg没有细胞毒性能力,但其抑制功能是细胞-细胞接触依赖性的,部分依赖于细胞毒性T淋巴细胞抗原4的表达。这种方法可能会加速基于Treg的免疫疗法在移植和自身免疫性疾病中的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号